Lenalidomide-induced immunophenotypic changes. (A) Effects of lenalidomide measured by CD4⁺ and CD25⁺ T-cell counts in peripheral blood mononuclear cells at day 28 compared with baseline (day 1). (B) Skin biopsy specimens analyzed for CD4⁺, CD8⁺, CD25⁺, and FoxP3⁺ T cells at day 28 compared with baseline (day 1). Each dot indicates single specimen at baseline and then after 1 cycle. A scatterplot was performed to determine differences of the immunologic components between 2 time points. The fitted regression line represents the trend in the data. Pt., patient.